About
About Ildong Holdings Co., Ltd
Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics. In addition, the company distributes medical devices, quasi drugs, health supplements, food products, beverages, cosmetics, sanitary ware, and other healthcare products through online; and manufactures original and generic prescription drugs. Further, it offers probiotics; pharmaceutical SI consulting, system development and deployment, RFID and barcode systems, and other solutions; and engages in advertising business. The company was formerly known as Ildong Pharmaceutical Co., Ltd. and changed its name to Ildong Holdings Co., Ltd. in August 2016. Ildong Holdings Co., Ltd. was founded in 1941 and is headquartered in Seoul, South Korea.
Research context
Ildong Holdings Co., Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
Apr 1, 2021
Ildong Holdings Co., Ltd is currently in a long term uptrend where the price is trading 6.5% above its 200 day moving average.
From a valuation standpoint, the stock is 96.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.3.
Ildong Holdings Co., Ltd's total revenue rose by 7.4% to $147B since the same quarter in the previous year.
Its net income has increased by 65.3% to $-12B since the same quarter in the previous year.
Finally, its free cash flow fell by 306.9% to $-3B since the same quarter in the previous year.
Based on the above factors, Ildong Holdings Co., Ltd gets an overall score of 4/5.